{"title":"莫蒂:针对一种独特形式的糖尿病的策略。","authors":"Ram K Garg","doi":"10.4103/jehp.jehp_1880_24","DOIUrl":null,"url":null,"abstract":"<p><p>Maturity-onset diabetes of the young (MODY) is a monogenic, autosomal dominant form of diabetes that typically presents before the age of 25. It is caused by mutations in single genes involved in insulin production and glucose regulation, leading to various subtypes, including Hepatocyte Nuclear Factor 1 Alpha-MODY (HNF1A-MODY), Glucokinase-MODY (GCK-MODY), Hepatocyte Nuclear Factor 4 Alpha-MODY (HNF4A-MODY), and Hepatocyte Nuclear Factor 1 Beta-MODY (HNF1B-MODY), each with unique clinical characteristics and treatment responses. For instance, HNF1B-MODY is often associated with renal anomalies, while HNF1A and HNF4A subtypes commonly respond well to sulfonylureas. Unlike Type 1 and Type 2 diabetes, MODY usually manifests as mild to moderate hyperglycemia, making tailored treatment essential. Genetic testing plays a critical role in diagnosis, guiding personalized management strategies that may include specific medications, lifestyle adjustments, and vigilant monitoring to mitigate complications. Preventive care, routine health check-ups, and comprehensive patient education are crucial for effective MODY management, ultimately enhancing the quality of life for individuals living with this condition.</p>","PeriodicalId":15581,"journal":{"name":"Journal of Education and Health Promotion","volume":"14 ","pages":"338"},"PeriodicalIF":1.3000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12448557/pdf/","citationCount":"0","resultStr":"{\"title\":\"MODY: Strategies for a unique form of diabetes.\",\"authors\":\"Ram K Garg\",\"doi\":\"10.4103/jehp.jehp_1880_24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Maturity-onset diabetes of the young (MODY) is a monogenic, autosomal dominant form of diabetes that typically presents before the age of 25. It is caused by mutations in single genes involved in insulin production and glucose regulation, leading to various subtypes, including Hepatocyte Nuclear Factor 1 Alpha-MODY (HNF1A-MODY), Glucokinase-MODY (GCK-MODY), Hepatocyte Nuclear Factor 4 Alpha-MODY (HNF4A-MODY), and Hepatocyte Nuclear Factor 1 Beta-MODY (HNF1B-MODY), each with unique clinical characteristics and treatment responses. For instance, HNF1B-MODY is often associated with renal anomalies, while HNF1A and HNF4A subtypes commonly respond well to sulfonylureas. Unlike Type 1 and Type 2 diabetes, MODY usually manifests as mild to moderate hyperglycemia, making tailored treatment essential. Genetic testing plays a critical role in diagnosis, guiding personalized management strategies that may include specific medications, lifestyle adjustments, and vigilant monitoring to mitigate complications. Preventive care, routine health check-ups, and comprehensive patient education are crucial for effective MODY management, ultimately enhancing the quality of life for individuals living with this condition.</p>\",\"PeriodicalId\":15581,\"journal\":{\"name\":\"Journal of Education and Health Promotion\",\"volume\":\"14 \",\"pages\":\"338\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12448557/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Education and Health Promotion\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jehp.jehp_1880_24\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"EDUCATION, SCIENTIFIC DISCIPLINES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Education and Health Promotion","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jehp.jehp_1880_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"EDUCATION, SCIENTIFIC DISCIPLINES","Score":null,"Total":0}
Maturity-onset diabetes of the young (MODY) is a monogenic, autosomal dominant form of diabetes that typically presents before the age of 25. It is caused by mutations in single genes involved in insulin production and glucose regulation, leading to various subtypes, including Hepatocyte Nuclear Factor 1 Alpha-MODY (HNF1A-MODY), Glucokinase-MODY (GCK-MODY), Hepatocyte Nuclear Factor 4 Alpha-MODY (HNF4A-MODY), and Hepatocyte Nuclear Factor 1 Beta-MODY (HNF1B-MODY), each with unique clinical characteristics and treatment responses. For instance, HNF1B-MODY is often associated with renal anomalies, while HNF1A and HNF4A subtypes commonly respond well to sulfonylureas. Unlike Type 1 and Type 2 diabetes, MODY usually manifests as mild to moderate hyperglycemia, making tailored treatment essential. Genetic testing plays a critical role in diagnosis, guiding personalized management strategies that may include specific medications, lifestyle adjustments, and vigilant monitoring to mitigate complications. Preventive care, routine health check-ups, and comprehensive patient education are crucial for effective MODY management, ultimately enhancing the quality of life for individuals living with this condition.